The results are in from the world’s largest study of ivermectin for COVID-19. Researchers in Brazil found that regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization and mortality rates.
The study was conducted in Itajaí, a port city in the state of Santa Catarina, between July and December 2020. Study authors include FLCCC physicians Dr. Flavio Cadegiani and Dr. Pierre Kory. Lead author Dr. Lucy Kerr was approached by the mayor of Itajaí, after the city began to experience a severe outbreak of COVID.The entire population of Itajaí was invited to participate in the program, which involved a medical visit to compile baseline, personal, demographic, and medical information.
In the absence of contraindications, ivermectin was offered as a preventative treatment, to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day.Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects elected to participate: over 70% opted to take ivermectin, and 23% chose not to.
The study found a 44% reduction in COVID-19 infection rate in favor of the group that took ivermectin (3.5% versus 8.2%).
Interestingly, the group who self-selected to take ivermectin was older and had more comorbidities than the group who opted for no treatment. These results show that prophylactic ivermectin may be a mitigating factor in groups with higher risk of morbidity.
The data demonstrate that using preventative ivermectin significantly lowers the infection rate, and that benefits outweigh the speculated increased risk of changes in social behaviors.
The peer viewed study is waiting for FDA approval.